Investors

Press Releases

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Press Releases

Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders

May 11, 2022

Enveric Biosciences to Host Fireside Chat with Dr. Bob Dagher, Chief Medical Officer, on May 17th at 10:00 a.m. ET

May 5, 2022

Enveric Biosciences Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

May 3, 2022

Enveric Biosciences to Participate in Upcoming Investor Conferences in April 2022

April 6, 2022

Enveric Biosciences Reports Full-Year 2021 Financial Results and Provides Business Update

March 31, 2022

Enveric Biosciences Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application

March 29, 2022

Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates

March 15, 2022

Enveric Biosciences to Participate in Upcoming Investor Conferences in March 2022

March 3, 2022

Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules

March 1, 2022

Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related Distress

February 17, 2022

‹
1
…
7
8
9
10
11
…
13
›

Company

Team

Psybrary™

Pipeline

Investors

Contact

Sign Up for Updates

© 2024 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.